Immunotherapy researchers are applying new insights into how the immune system works to unleash its power on cancer and fight autoimmune diseases like diabetes, MS and rheumatoid arthritis. Private investors, VCs, and pharmaceutical companies are investing hundreds of millions of dollars into groundbreaking immunotherapies, and clinicians are scrambling to identify and test the most promising treatments.
In spite of the huge expense, time-consuming research, rigorous clinical testing, and FDA approval requirements, startups, non-profit organizations, and established companies alike are racing to bring the next immunotherapy to market. Radically different approaches will stand alone, be combined, or fail in crunch time. According to market research firm MarketsandMarkets, the global immunotherapy market is expected to grow at a CAGR of 13.5%, reaching $201B by 2021, promising huge returns.
Biopharma companies like Merck, Novartis, Roche and BMS are all-in. With high barriers to entry, are startups able to compete? What strategies are companies taking to be the first to market? Will cancer, allergies, and autoimmune disease someday be a thing of the past?
Tito Serafini, President and CEO, Founder, Atreca
Jonathan MacQuitty, CEO, Forty Seven Inc.
Karin Jooss, Executive Vice President of Research & Chief Scientific Officer, Gritstone Oncology
Edgar Engleman, Professor of Pathology and of Medicine, Stanford University
Jackie Benson, Vice President, Immunology Scientific Innovation, Johnson & Johnson
Brian Taylor, Lynne Sopchak, June Power, Trivedi Madhuri, Joellen Brown, Michael Chen, KY Narasimhan, Shibu Gangadharan, Fred Stein, Souradeep Sen
Tickets will be available at the door for $55
Can’t Make It To Menlo Park? LIVESTREAM TICKETS ARE AVAILABLE, TOO!